Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599284 | 0.73 | PI4KA (0.32) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17892682 | 0.72 | PI4KA (0.35) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL63354 | 0.70 | CDK1 (0.61) | CYP1A2MAPK1ADORA2AADORA2B | |
| SCHEMBL17901712 | 0.70 | NSD2 (0.34) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4599282 | 0.70 | CCNB2 (0.36) | MAPK1 | |
| SCHEMBL9705370 | 0.69 | PI4KA (0.37) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6699970 | 0.69 | PI4KA (0.59) | ADORA2AADORA2BPI4KAPI4K2BPI4K2A | |
| SCHEMBL62675 | 0.69 | TSHR (0.36) | CYP1A2MAPK1ADORA2AADORA2B | |
| SCHEMBL13718046 | 0.68 | FLT4 (0.35) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8495356 | 0.65 | CSF1R (0.36) | CYP1A2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926703-B1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS BV (NL) | 2013-01-09 | — | — | EP | disclosed |
| US-8129562-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2012-03-06 | — | — | US | disclosed |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. | 2011-05-26 | — | — | US | disclosed |
| US-7906496-B2 | Carboxylic acid derivatives | DSM IP ASSETS B.V. (NL) | 2011-03-15 | — | — | US | disclosed |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | DSM ASSETS B.V. (NL) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | AADAC, ALDH7A1, DDC | CYP1A2 200/4885CYP2D6 470/4885MAPK1 4152/4885 |
| US-20110124726-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | AADAC, ALDH7A1, ALDH18A1 | CYP1A2 160/4885CYP2D6 444/4885MAPK1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.